Compass Therapeutics, Inc. — Fiscal 2020 Form 10-K Summary
Business context and reporting period
Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics for solid tumors, hematological malignancies and autoimmune indications. The filing covers the fiscal year ended December 31, 2020; the company does not report quarterly Q4 results separately in the provided text.
Lead candidate CTX-471, a CD137 agonist, was in an ongoing Phase 1 trial. CTX-8371, a PD-1 x PD-L1 bispecific antibody, was in IND-enabling studies. In early 2021, management deprioritized its NKp30 innate cell engager platform and discontinued efforts to advance CTX-8573 to IND-enabling studies.
Financial condition and key metrics
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | No product revenue | No product revenue | None |
| Research and development expense | $14.9 million | $22.4 million | Down $7.5 million |
| General and administrative expense | $12.9 million | $11.6 million | Up $1.3 million |
| Total operating expenses | $27.8 million | $34.1 million | Down $6.2 million |
| Operating loss | $27.8 million | $34.1 million | Improved by $6.2 million |
| Net loss | $29.5 million | $34.7 million | Improved by $5.2 million |
| Basic and diluted loss per share | $0.96 loss | $5.19 loss | Improved |
| Cash used in operating activities | $26.8 million | $31.7 million | Use decreased by $4.9 million |
| Cash and cash equivalents at year-end | $47.1 million | $25.3 million | Up $21.8 million |
| Debt | $9.3 million | $14.9 million | Down $5.5 million |
| Working capital | $40.1 million | $16.4 million | Up $23.7 million |
| Stockholders’ equity | $39.9 million | $(118.6) million | Improved substantially |
Cash provided by financing activities was $48.5 million, primarily from the June 2020 private placement, which generated $60.5 million of gross proceeds and $54.2 million of net proceeds after issuance costs. Cash provided by investing activities was $38 thousand.
Debt consisted primarily of the Pacific Western Bank 2018 Credit Facility. The facility bears interest at the greater of 6.25% or prime plus 2.0%, matures March 1, 2022, and required $625 thousand of monthly principal payments beginning in April 2020. The company was in compliance with its covenants at December 31, 2020 and was required to maintain a minimum cash balance of $6.0 million.
Material changes versus the prior comparable period
- Research and development expense declined 34%, primarily because CTX-471 transitioned into clinical development, preclinical work was completed, the company reduced its research and development workforce, and no comparable Adimab milestone payment was made in 2020.
- CTX-8371-related research and development spending increased to $1.5 million from $34 thousand as IND-enabling work began.
- General and administrative expense increased because of higher stock-based compensation and public-company legal and professional costs, partly offset by lower headcount-related costs.
- Interest expense declined as the company began repaying principal under the credit facility. The $1.1 million lender success fee was paid in connection with the June 2020 merger.
- The June 2020 reverse merger converted Compass Therapeutics into a public reporting company and eliminated the outstanding convertible preferred stock through conversion into common shares.
- On March 4, 2021, the common stock was cleared for trading on the OTCQB Venture Market under the symbol CMPX.
Guidance, outlook, commentary and risks
- Management expected to complete the CTX-471 Phase 1b dose-expansion stage in the second half of 2021 and target a Phase 2/3 trial in the second half of 2022, subject to results and additional funding.
- As of February 28, 2021, 11 patients had received CTX-471 in Phase 1b; six had reached the first tumor evaluation, five had stable disease, and one later achieved a partial response. No treatment-related serious adverse events had been reported in Phase 1b as of that date.
- Management targeted an IND submission for CTX-8371 in early 2022 and potentially early safety and top-line data later in 2022.
- Existing cash and cash equivalents were expected to fund operating expenses and capital expenditures into the second quarter of 2022. The company stated that substantial additional financing will be required and that the estimate could prove inaccurate.
- The company has never generated product-sales revenue, expects continuing operating losses and may never achieve profitability. Its accumulated deficit was $151.4 million at December 31, 2020.
- Key risks include clinical-trial failure or delay, limited early-stage clinical data, safety risks associated with CD137 agonism and bispecific antibodies, regulatory uncertainty, reliance on contract research and manufacturing organizations, intellectual-property challenges, competition, COVID-19 disruptions and future dilution or restrictive financing terms.
- Contractual commitments included $9.8 million of principal and interest on long-term debt, $6.1 million of operating lease commitments and $2.2 million of manufacturing commitments. Potential license milestones and royalties were excluded where timing or likelihood was uncertain.
Most important facts for investors to verify
- Verify the audited financial statements, including the absence of product revenue, $29.5 million net loss, $47.1 million cash balance and $9.3 million debt balance.
- Assess whether CTX-471’s small, early-stage clinical dataset supports progression to later-stage trials, particularly the reported stable disease and single partial response.
- Monitor cash burn, debt maturities and the timing, terms and dilution associated with required future financing.
- Verify the status of CTX-8371’s IND-enabling program and any subsequent IND submission or clinical data.
- Review the impact of the decision to discontinue CTX-8573 and deprioritize the NKp30 platform on pipeline value and resource allocation.
- Evaluate intellectual-property ownership, the Adimab license obligations, patent prosecution status and potential milestone or royalty payments.
- Consider the liquidity and volatility risks associated with OTCQB trading, concentrated ownership and the absence of dividends.